ERBB2 and neoplasm: Dr. Wicha's group has elegantly summarized and proposed to target CSC via CSC surface markers, such as ALDH (aldehyde dehydrogenase), CD44, CD133 and HER2, or the CSC niche, such as tumor associated macrophages and myeloid-derived suppressor cells, using immunologic approaches [27].